Pragmatic adjunctive usage of netarsudil: A retrospective chart review from a tertiary care center

Simple item page
dc.contributor.authorGoergen, Nate Sen_US
dc.contributor.authorGagrani, Meghalen_US
dc.contributor.authorGulati, Vikasen_US
dc.contributor.authorGhate, Deeptaen_US
dc.date.accessioned2023-08-25T06:34:07Z
dc.date.available2023-08-25T06:34:07Z
dc.date.issued2022-08
dc.description.abstractPurpose: This retrospective chart review of netarsudil (Rhopressa) characterizes intra-ocular pressure (IOP) reduction, drug tolerance, drug cost, and compliance in a tertiary university Midwest clinic in a variety of glaucoma diagnoses on patients prescribed netarsudil 01/2017 to 5/2020. Methods: Patient demographics, primary diagnosis, indication for medication, prescription date, prescription fill status, duration of use, discontinuation reason, and number of IOP-lowering medications were noted. Confounding medication changes were excluded from IOP analysis. The IOP difference between the first visit after starting netarsudil and the baseline (mean before starting netarsudil on the stable medication regimen) was calculated. Results: A total of 133 patients were prescribed netarsudil (age 69 ± 20 years, 59% females, 79% white, 86% primary glaucoma) as adjunct glaucoma medication (mean medications 3.2 ± 0.9). Indications were lowering IOP (mean baseline IOP 20.0 ± 6 mmHg) and drug regimen simplification. Prescription was not filled by 22/133 subjects because of the cost (68%) and the need for surgery (23%). No demographic factors were associated with prescription fill status. A total of 101 eyes of 76 patients were used for IOP analysis. The mean change in IOP was –0.8 ± 6.4 mmHg, (IOP decrease in 67%, increase or no change in 33% eyes). Netarsudil was discontinued in 52% (50/96) patients; the reasons include surgery for IOP control (42%), allergies (30%), cost (14%), and paradoxical rise in IOP (12%). Conclusion: Netarsudil was used as adjunct third or fourth line medication at a glaucoma practice in Midwestern USA. 17% of prescriptions went unfilled; netarsudil was discontinued in 52% of patients. IOP response was variable in this population with severe complex glaucoma.en_US
dc.identifier.affiliationsDepartment of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, NE, USAen_US
dc.identifier.affiliationsDepartment of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USAen_US
dc.identifier.affiliationsDepartment of Ophthalmology, Emory School of Medicine, Atlanta, GA, USAen_US
dc.identifier.citationGoergen Nate S, Gagrani Meghal, Gulati Vikas, Ghate Deepta. Pragmatic adjunctive usage of netarsudil: A retrospective chart review from a tertiary care center. Indian Journal of Ophthalmology. 2022 Aug; 70(8): 2906-2910en_US
dc.identifier.issn1998-3689
dc.identifier.issn0301-4738
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/224514
dc.languageenen_US
dc.publisherAll India Ophthalmological Societyen_US
dc.relation.issuenumber8en_US
dc.relation.volume70en_US
dc.source.urihttps://doi.org/10.4103/ijo.IJO_2947_21en_US
dc.subjectGlaucomaen_US
dc.subjectintra-ocular pressureen_US
dc.subjectnetarsudilen_US
dc.titlePragmatic adjunctive usage of netarsudil: A retrospective chart review from a tertiary care centeren_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJO2022v70n8p2906.pdf
Size:
1.3 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Ophthalmology